CSL joins forces with Alentis on claudin candidate
CSL has licensed rights to a potentially first-in-class anti-claudin-1 antibody developed by Alentis in a deal that could be worth up to $1.55bn.
Bayer pledges $2.2bn to US manufacturing facility
Bayer has joined the ranks of pharma groups planning major facility investments in the US, with a $2.2bn plan for a new production unit in Ohio.
Novartis taps China's Abogen for autoimmunity TCE
Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.
Everlywell rolls out Clairity AI for breast cancer in US
Digital health firm Everlywell is rolling out a Clairity AI, which can assess the risk of developing breast cancer from a mammogram, across the US.
New diabetes and obesity studies making waves at EASD
As the EASD congress draws to a close, here's a round-up of some of the other clinical trials in diabetes and obesity that drew our attention.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
3rd Annual Personalized Cancer Vaccine Summit 2026 | Decembe...
The 3rd Annual Personalized Cancer Vaccine Summit brings together leaders from across companies to share data-driven insights
CPHI Milan 2026 showcases new Sustainability Summit
The first-time event will bring delegates together to discuss sustainability challenges
Pharmaceutical thought leaders gather at CPHI Milan 2026
Industry leaders will address topics such as manufacturing transformation and future therapies
5th Sustainability in Life Sciences Summit
Join the global sustainability community this November in Boston
CPHI Milan Leadership Summit returns for 2026
Senior pharma leaders will tackle resilience, policy, and industry transformation at CPHI Milan